Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LidoDyn
- Development stage
- Phase 2
- Lead developer
- Teikoku Pharma
- Modality
- Small Molecules
- Administration
- Topical
01
Overview
LidoDyn is an investigational **topical anesthetic formulation** evaluated by Rambam Health Care Campus for reducing pain associated with venipuncture in children. The registered trial describes it as containing **5% lidocaine** plus an unspecified disinfection ingredient and compared it with EMLA cream. Lidocaine produces local anesthesia through reversible, activity-dependent blockade of voltage-gated sodium channels in peripheral nerves, preventing action-potential propagation and transiently reducing pain sensation.
- Other names
- LidoDyn
02
Targets
SCN5A (Sodium channel protein type 5 subunit alpha)
Beyond the preview
Go deeper on LidoDyn.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LidoDyn.